Author Profile

Insilico Advances AI-Empowered TNIK Inhibitor into Phase 3
The company used AI to prioritize the novel target as well as to generate and optimize the small molecule. read more
Grünenthal Gets Orphan, Rare Pediatric Disease Tags for Duchenne Drug
The orally-available compound could provide an alternative to conventional glucocorticoids, the current standard of care. read more
Data in Hand, Compass Psychedelic on Track for Q4 NDA Submission
A rolling NDA submission for treatment-resistant depression with the FDA is underway. read more
FDA Accepts Pharvaris NDA for Oral HAE Drug
If approved, deucrictibant will be the first oral bradykinin B2 receptor antagonist to treat HAE attacks. read more
Vertex to Buy Crinetics for $10B
Vertex will pick up an FDA-approved oral therapy for acromegaly and a phase 3 drug to treat CAH. read more
AstraZeneca, Abbisko Partner on Oral PD-L1/Tagrisso Combo Trial
The phase 1/2 study will evaluate the combo in EGFR-mutated and PD-L1 positive locally advanced or metastatic NSCLC. read more
NEJM Retracts Pivotal Publication for Amgen’s Tavneos
The retraction comes amid increasing regulatory scrutiny of the drug. read more
Creating Amorphous Solid Dispersions via Spray Drying
Spray-dried ASDs are increasingly used to improve bioavailability for complex new molecules, making efficient process development tools and methodologies essential for accelerating commercialization. read more
When AI Isn't Enough
While AI offers significant advantages in data processing and analytical capability, its use in regulated industries must be carefully governed. Organizations must balance innovation with compliance by ensuring robust data ... read more
Otsuka Novel ADHD Drug Posts Phase 3 Win
Centanafadine was granted Priority Review and has a PDUFA target action date of July 24, 2026. read more
STADA Buys Consumer Health Portfolio from Orifarm
The company is adding leading brands to its portfolio to boost its position in Belgium, Poland, and the Nordics. read more
Calico Gets Breakthrough Therapy Tag for Ultra-Rare Brain Disease Drug
The phase 1b/2 trial will be the first time that an eIF2B is administered to people with VWM disease. read more
Definium Single-Dose Psychedelic ODT Hits the Mark in Depression Study
DT120 is a lysergamide compound — an LSD derivative — administered as a single 100 µg orally disintegrating tablet. read more
Nortiva Bio Launches to Develop Long-Acting Oral Meds
The company's proprietary drug delivery platform replaces daily pills with a once-monthly capsule that releases a stable dose. read more
GSK, Spero Win First FDA Nod for Oral Carbapenem for Complicated UTIs
Complicated urinary tract infections have historically required IV treatment when standard oral options fail. read more
Lilly Buys Non-Opioid Pain Drugmaker 4E
The acquisition gives Lilly a pipeline of orally-available MNK inhibitors for treating chronic pain. read more
AstraZeneca Advances Oral GLP-1 into Phase 3
The drugmaker will advance elecoglipron into an extensive phase 3 program in obesity and type 2 diabetes. read more
Perrigo CEO Resigns Over Personal Conduct Issues
While the board searches for a permanent successor, Albert Manzone will act as interim president and CEO. read more
Neumora Scraps Oral Depression Drug, Cuts Workforce by 35%
Navacaprant failed to lead to improvement compared to a placebo. read more
Gilead, Merck Share Pair of Phase 3 Wins for Once-Weekly HIV Pill
The regimen treats virologically-suppressed patients who have switched from Biktarvy. read more

May/June 2026

2026 Annual Buyer’s Guide
View Issue

Subscribe to Tablets & Capsules

Get started here for your complimentary print or digital subscription

Get started here for your complimentary print or digital subscription
Sign up Now »

Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox!